AR114666A1 - Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer - Google Patents

Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer

Info

Publication number
AR114666A1
AR114666A1 ARP190100547A ARP190100547A AR114666A1 AR 114666 A1 AR114666 A1 AR 114666A1 AR P190100547 A ARP190100547 A AR P190100547A AR P190100547 A ARP190100547 A AR P190100547A AR 114666 A1 AR114666 A1 AR 114666A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
ring
hydrogen
membered
Prior art date
Application number
ARP190100547A
Other languages
English (en)
Spanish (es)
Inventor
William R Baker
Original Assignee
Celgene Int Ii Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Int Ii Sarl filed Critical Celgene Int Ii Sarl
Publication of AR114666A1 publication Critical patent/AR114666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ARP190100547A 2018-03-07 2019-03-06 Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer AR114666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
AR114666A1 true AR114666A1 (es) 2020-09-30

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100547A AR114666A1 (es) 2018-03-07 2019-03-06 Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer

Country Status (11)

Country Link
US (1) US11639332B2 (cg-RX-API-DMAC10.html)
EP (1) EP3762365B1 (cg-RX-API-DMAC10.html)
JP (1) JP7396991B2 (cg-RX-API-DMAC10.html)
AR (1) AR114666A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019229583B2 (cg-RX-API-DMAC10.html)
CA (1) CA3093196A1 (cg-RX-API-DMAC10.html)
ES (1) ES2987705T3 (cg-RX-API-DMAC10.html)
MA (1) MA52266A (cg-RX-API-DMAC10.html)
MX (1) MX2020009288A (cg-RX-API-DMAC10.html)
TW (1) TW202000646A (cg-RX-API-DMAC10.html)
WO (1) WO2019170750A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
KR20030026936A (ko) * 2000-06-29 2003-04-03 니폰 가야꾸 가부시끼가이샤 색소증감 광전 변환소자
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2008270363A1 (en) * 2007-06-29 2009-01-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Targeting diazo prodrugs for the treatment of gastrointestinal diseases
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas

Also Published As

Publication number Publication date
ES2987705T3 (es) 2024-11-15
JP7396991B2 (ja) 2023-12-12
JP2021517134A (ja) 2021-07-15
EP3762365B1 (en) 2024-02-21
AU2019229583B2 (en) 2024-06-13
US11639332B2 (en) 2023-05-02
AU2019229583A1 (en) 2020-09-10
MA52266A (fr) 2021-01-13
TW202000646A (zh) 2020-01-01
US20200392082A1 (en) 2020-12-17
CA3093196A1 (en) 2019-09-12
MX2020009288A (es) 2020-09-28
EP3762365A1 (en) 2021-01-13
WO2019170750A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR088449A1 (es) Benzilindazoles sustituidos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
MX2017011650A (es) Inhibidores de kv1.3 y su aplicacion medica.
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco

Legal Events

Date Code Title Description
FB Suspension of granting procedure